Summary We report a constitutional point mutation of codon 278 in exon 8 of the TP53 gene that has not yet been described as a germ-line mutation. A 52-year-old female developed multiple primary malignancies (liposarcoma, breast cancer, malignant histiocytoma, occult adenocarcinoma). The mutation found in her tumour and peripheral blood lymphocyte DNA is a cytosine to thymine transition at the second position of codon 278 resulting in an amino acid exchange from proline to leucine in the DNA-binding domain. Evaluation of the patient's family revealed that both of her sons were affected by the same mutation. Although the patient's mother had died already, we were able to demonstrate by polymorphic microsatellite analysis that the defective allele originated from the maternal side. As four brothers and one sister had inherited the same allele, which however was wild type, we were able to show that the mutation must have occurred in the germ cells of the patient's mother and that it may therefore be called de novo. This explains the lack of a high cancer incidence in the family history. All tumours tested showed positive immunohistochemical staining for p53. Loss of heterozygosity was found in five of seven tumours, one showing chromosome 17 monosomy.
According to Knudson' s two-hit hypothesis, the most striking difference between sporadic and inherited cancer is that in the latter the number of steps in oncogenesis is reduced by one. Genes mutated in hereditary cancer are tumour-suppressor genes. Germ-line mutations of these genes predispose carriers to cancer development. These 'family cancer genes' are called 'recessive' cancer genes since one normal allele is enough to protect against cancer (Knudson, 1985) . The second hit, resulting in cancer development is supposed to be either an allelic deletion leading to a loss of heterozygosity (LOH), a second point mutation occurring in the wild-type allele or a functional inactivation of the wild-type protein . Lane (1992) described the TP53 gene as a 'guardian of the genome', acting to protect cells from genetic damage by inducing either DNA repair of apoptosis, which appear to be important mechanisms for eliminating abnormal cells. Inactivation of this cell cycle control function of p53 either by mutations or complex formation with certain proteins may result in accumulation of mutated p53 protein and in genetic instability, a key factor in neoplastic pathogenesis and tumour progression.
TP53 mutations were initially identified as the major genetic basis of the Li-Fraumeni and the Li-Fraumeni-like syndrome (Malkin et al., 1990; Srivastava et al., 1990) , an autosomal dominant predisposition to cancer development (Li and Fraumeni, 1969; Birch et al., 1994) . In such families, cancer development occurring at unusually early ages appears to segregate with the presence of a germ-line TP53 mutation.
In this study we describe a 52-year-old patient who developed multiple primary tumours reminiscent of a constitutional TP53 mutation. Since it has been shown that the highly conserved regions of TP53 are mutational hotspots both in sporadic and in hereditary cancers (Soussi et al., 1990; Levine et al., 1991; Caron de Fromentel and Soussi, 1992) we investigated the coding sequences of exons 5-8, applying a combination of temperature gradient gel electrophoresis (TGGE) and direct sequencing. To demonstrate a possible p53 overexpression, the patient's tumours were analysed immunohistochemically. Analysis of microsatellite polymorphisms and fluorescence in situ hybridisation (FISH) were used to detect possible allelic imbalances, such as deletions at the TP53 locus, aberrations of the chromosome 17 copy number and intratumoral heterogeneity. Furthermore, we screened all first and second degree family members alive for TP53 mutations and performed haplotype analysis. Genetic and immunohistochemical findings are reported.
Methods

DNA extraction
For DNA extraction, two 30 gim paraffin sections of each tumour were treated as described (Speiser et al., 1996 fragment IV). Primer sequences were chosen from the TP53 cDNA sequence (Zakut Houri et al., 1985) . The sense primers contained the sequence for a previously described 40 bp 'GCclamp' (Sheffield et al., 1989 Microdissection and analysis of microsatellite polymorphisms To enrich for tumour cells, 8 pm sections of formalin-fixed paraffin-embedded tumours were subjected to microdissection as described (Speiser et al., 1996) . Microsatellite analysis was performed for highly polymorphic dinucleotide repeat polymorphism at the loci TP53 (Jones and Nakamura 1992) and D17S786 (Gyapay et al., 1994 ) with primer and conditions described there.
RFLP analysis
For the analysis of the intragenic RFLP (exon 4, BstUl) a 259 bp fragment was amplified by PCR and analysed on a 4% (3/1 NuSieve/GTG-Agarose) agarose gel as described by Greenwald et al. (1992) . Immunohistochemistry Sections (3 pm) were cut, deparaffinised and fixed on poly-Llysine-coated slides at room temperature. The sections were stained with high-affinity anti-p53 monoclonal antibody DO-1 (Vojtesek et al., 1992) using the staining protocol previously described by Midgly et al. (1992) with the difference in the streptavidin -biotin step (Biogenex Super Sensitive system was used instead of Vector kit). 3,3-diaminobenzidine in 0.03% nickel sulphate was used as chromogen. In addition, a further three monoclonal antibodies to p53 protein, i.e. BP53.12, PAb 421, DO-7, and anti-p53 rabbit antiserum CM-1, were used in parallel for the comparisons but the results owing to minor difference in the staining intensity as compared with DO-1 are not presented in detail.
Fluorescence in situ hybridisation Dissociation of nuclei was as previously described (Sauter et al., 1995a) . The chromosome 17 centromere probe pl7H8 was digoxigenated by nick translation. Cells on slides were denatured in 70% formamide/2 x sodium saline citrate (SSC) (1 x SSC is 0.15 M sodium chloride, 0.015 M sodium citrate), pH 7, at 75°C. The hybridisation mixture (10 Ml) consisted of 30 ng of the centromere probe and 10 ng unlabelled sonicated herring sperm DNA in 55% formamide, 10% dextran sulphate and 2 x SSC (pH 7). After hybridisation the slides were washed in 55% formamide/2 x SSC, pH 7 at 45°C. Immunohistochemical probe detection using FITC-conjugated sheep anti-digoxigenin (Vector) and FITC-conjugated sheep anti-digoxigenin (Sigma) was described previously (Sauter et al., 1995a) . For each case, the centromere 17 count was scored in 100 cells. Monosomic cell counts below 10% do not indicate allelic loss, since this can also be found in normal tissue and is generally attributed to an inefficient hybridisation.
Results
Patient characteristics
The 52-year-old female patient had developed multiple primary malignancies (Table I) , including liposarcoma of the left arm (TI) at age 40, Paget's disease and a concomitant intraductal carcinoma of the left breast (T2) at 42, Paget's disease and a concomitant ductal carcinoma in situ of the right breast (T3) at 45, two independent malignant histiocytomas of the biceps muscle of the left arm (T4) at 48 and of the pelvis (T5) at 49. One year later, when she was operated on for a pelvic recurrence of histiocytoma (T6), a metastasis of an adenocarcinoma of unknown origin was found in the omentum majus (T7).
Detection of a TP53 germ-line mutation To screen lymphocyte and tumour DNA for mutations in the TP53 gene, regions spanning exons 5 to 8 were amplified by polymerase chain reaction (PCR). PCR products were subjected to TGGE analysis to detect bands with altered electrophoretic mobility. All tumours exhibited a band pattern that was in line with a possible mutation in exon 8. This pattern was also found in the DNA of the patient's peripheral blood lymphocytes (PBLs), indicating that the mutation was constitutional (Figure 1 ). All PCR products exhibiting this band pattern were directly sequenced. At position 2 in codon 278 a cytosine to thymine (C--T) Family screening and haplotype analysis Exact construction of the patient's pedigree (Figure 2 ) did not reveal a high cancer incidence in the family history. The patient's mother had died of an unknown disease at age 50. One sister of her eight siblings had died of post-operative thromboembolism. DNA from PBLs of the patient's family was subjected to PCR-TGGE analysis of exon 8, which revealed that her daughter, five brothers, two sisters, father and aunt (maternal side) harboured wild-type alleles only. Both of her sons, however, displayed the same band pattern as their mother (Figure 1 ) and direct sequencing of the PCR products showed that they had inherited the mutant allele. To study haplotype associations (Figure 2 ), family members were typed using the microsatellite polymorphisms at or near TP53 (D17S768, TP53) and an intragenic RFLP (exon 4, BstUl) (data not shown). We were able to demonstrate that the defective allele originated from the maternal side because the patient's aunt, four of her brothers and one of her sisters had inherited the same allele, which however, was wild-type. The patient's two sons had also inherited this allele, but in the mutant form.
Allelic imbalance in the tumours In four tumours we detected LOH both at TP53 and at D17S768 (Table I, Figure 3 ). This was in line with the observation that on TGGE analysis the mutated homoduplex band was stronger than the wild-type homoduplex band (Figure 1) 
Discussion
In this study we report a constitutional point mutation at codon 278 in exon 8 of the TP53 tumour-suppressor gene in a patient with multiple primary malignancies. This particular mutation has not yet been reported as a germ-line mutation. The mutant allele was also detected in the PBLs-DNA of the patient's two sons, but not in the other family members tested. The patient's aunt and five siblings carry this allele in a non-mutated form, which corroborates the hypothesis of a de novo mutation and suggests that the patient is the founder of a new cancer-prone family.
Codon 278 is not a mutational hot spot in sporadic cancer. Reviewing over 2500 cases of TP53 mutations, Hollstein et al. (1994) found only 31 mutations at codon 278 and three C--T transitions at position 2 (Sameshima et Hollstein et al., 1990) .
The C-+T transition at position 2 is located in the DNAbinding domain (Cho et al., 1994) and results in an amino acid exchange from proline to leucine. It is likely that this exchange has an influence on the protein structure, since Figures 1 and 3 ). This is in accordance with Knudson's two-hit hypothesis for the role of tumour-suppressor genes in neoplasia (Knudson, 1985 
Oliner et al., 1992) . Interference with such a protein would probably affect p53 activity, thus being the proposed 'second hit'. However, the nature of such another fundamental event apart from the point mutation is unclear at present.
The finding of a marked chromosome 17 heterogeneity with several separate polysomic populations in two tumours is consistent with the postulated role of p53 in terms of preserving genomic stability. This is in line with our findings that more than three polysomic populations occur almost exclusively in tumours with a p53 alteration (Sauter et al.. 1995b) .
There is strong evidence that some germ-line TP53 mutations are closely related to cancer development in their carriers, because in p53 families early cancer development is associated with the presence of the germ-line mutation. To this point, we have not yet been able to prove that cancer in our patient was indeed caused by the constitutional TP53 mutation but we believe that there is ample evidence to support this notion: (1) the affected codon lies in a highly conserved domain: (2) the mutation leads to an amino acid exchange in the DNA-binding domain, resulting in a conformational change and in stabilisation of the protein; (3) the mutation seems to play a role in the development of sporadic cancer; (4) frequent loss of the wild-type allele in the tumours has been demonstrated; and (5) the mutant allele coincides with the development of multiple primary cancers.
Reviewing the spectrum of tumours and the age of onset that were reported in TP53 germ-line mutation carriers. Birch et al. (1994) separated classical Li-Fraumeni syndrome families from families exhibiting some but not all of the features of Li -Fraumeni syndrome. In classical LiFraumeni syndrome families, TP53 germ-line mutations are much more common than in other cancer-prone families. As to the histological type of her tumours. our patient fits into both groups described. The future family history will decide to which of the two groups they actually belong.
